XM does not provide services to residents of the United States of America.
A
A

AstraZeneca

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

US natural gas prices drop to 7-week low on rising output, high storage levels

UPDATE 1-US natural gas prices drop to 7-week low on rising output, high storage levels Adds latest prices July 5 (Reuters) - U.S. natural gas futures slipped over 4% to a seven-week low on Friday, as rising output and ample gas supply in storage outweighed support from forecasts for higher demand over the next two weeks. Front-month gas futures NGc1 for August delivery on the New York Mercantile Exchange fell 9.5 cents , to settle at $2.31 9 per million British thermal units (mmBtu).
A

US natural gas prices drop to 7-week low on rising output, high storage levels

US natural gas prices drop to 7-week low on rising output, high storage levels July 5 (Reuters) - U.S. natural gas futures slipped nearly 2% to a seven-week low on Friday, as rising output and ample gas supply in storage outweighed support from forecasts for higher demand over the next two weeks. Front-month gas futures NGc1 for May delivery on the New York Mercantile Exchange were down 4.6 cents, or 1.9%, to $2.37 per million British thermal units (mmBtu) at 10:57 a.m.
A
N

Anti-TIGIT drugmakers down as Roche's lung cancer drug fails trial

BUZZ-Anti-TIGIT drugmakers down as Roche's lung cancer drug fails trial Updates ** U.S.-listed shares of Israel-based therapy developer Compugen CGEN.TA fall ~3% to $1.62 premarket ** Switzerland-based Roche's ROG.S drug tiragolumab, which is part of a new class of drugs known as anti-TIGIT, failed a lung cancer treatment trial on Thursday ** CGEN
A
R

Compugen down as Roche's 'anti-TIGIT' lung cancer drug fails trial

BUZZ-Compugen down as Roche's 'anti-TIGIT' lung cancer drug fails trial ** U.S.-listed shares of Israel-based therapy developer Compugen CGEN.TA fall ~3% to $1.62 premarket ** Switzerland-based Roche's ROG.S drug tiragolumab, which is part of a new class of drugs known as anti-TIGIT, failed a lung cancer treatment trial on Thursday ** CGEN has colo
A
R

AstraZeneca Says Tagrisso With Addition Of Chemotherapy Approved In EU

BRIEF-AstraZeneca Says Tagrisso With Addition Of Chemotherapy Approved In EU July 5 (Reuters) - AstraZeneca PLC AZN.L : TAGRISSO WITH THE ADDITION OF CHEMOTHERAPY APPROVED IN THE EU AS NEW 1ST-LINE TREATMENT FOR PATIENTS WITH EGFR-MUTATED ADVANCED LUNG CANCER SAFETY PROFILE OF TAGRISSO PLUS CHEMOTHERAPY CONSISTENT WITH ESTABLISHED PROFILES OF INDIV
A

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.